Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCN13 shRNA is a short hairpin RNA construct designed to specifically silence the expression of the Lipocalin 13 (LCN13) gene. LCN13 is a secreted protein, or hepatokine, that belongs to the lipocalin family and plays a critical role in regulating systemic glucose homeostasis and insulin sensitivity. In metabolic research, LCN13 has been identified as a downstream target of the transcriptional cofactor TSC22D4; while TSC22D4 inhibition typically promotes LCN13 expression to improve metabolic profiles, the use of LCN13 shRNA serves to knock down the protein, thereby antagonizing its insulin-sensitizing effects. This molecular tool is primarily utilized in preclinical research to investigate the hepatic pathways governing glucose metabolism and to validate LCN13 as a potential therapeutic target for obesity-related insulin resistance and type 2 diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LCN13 shRNA.